- Home
- ARBK vs ABVC Comparison
ARBK vs ABVC Comparison
Compare ARBK & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARBK
- ABVC
- Stock Information
- Founded
- ARBK 2017
- ABVC 2015
- Country
- ARBK United Kingdom
- ABVC United States
- Employees
- ARBK N/A
- ABVC N/A
- Industry
- ARBK Finance: Consumer Services
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- ARBK Finance
- ABVC Health Care
- Exchange
- ARBK Nasdaq
- ABVC Nasdaq
- Market Cap
- ARBK 20.1M
- ABVC 22.1M
- IPO Year
- ARBK 2021
- ABVC N/A
- Fundamental
- Price
- ARBK $0.30
- ABVC $3.97
- Analyst Decision
- ARBK Hold
- ABVC
- Analyst Count
- ARBK 1
- ABVC 0
- Target Price
- ARBK N/A
- ABVC N/A
- AVG Volume (30 Days)
- ARBK 28.3M
- ABVC 711.2K
- Earning Date
- ARBK 08-27-2025
- ABVC 08-13-2025
- Dividend Yield
- ARBK N/A
- ABVC N/A
- EPS Growth
- ARBK N/A
- ABVC N/A
- EPS
- ARBK N/A
- ABVC N/A
- Revenue
- ARBK $47,017,000.00
- ABVC $508,383.00
- Revenue This Year
- ARBK $183.90
- ABVC $735.18
- Revenue Next Year
- ARBK $26.78
- ABVC N/A
- P/E Ratio
- ARBK N/A
- ABVC N/A
- Revenue Growth
- ARBK N/A
- ABVC 1904.43
- 52 Week Low
- ARBK $0.15
- ABVC $0.40
- 52 Week High
- ARBK $1.99
- ABVC $5.48
- Technical
- Relative Strength Index (RSI)
- ARBK 46.56
- ABVC 64.80
- Support Level
- ARBK $0.24
- ABVC $3.28
- Resistance Level
- ARBK $0.32
- ABVC $4.95
- Average True Range (ATR)
- ARBK 0.06
- ABVC 0.58
- MACD
- ARBK -0.00
- ABVC 0.15
- Stochastic Oscillator
- ARBK 46.42
- ABVC 58.40
About ARBK Argo Blockchain plc
Argo Blockchain PLC is a data center business that provides a powerful and efficient platform for cryptocurrency mining operations. The company has operations in strategic locations in North America.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.